Atrial fibrillation/flutter or supraventricular tachycardias, maintenance of sinus rhythm. Ventricular arrhythmias (prevention) Off-label use：Atrial fibrillation/flutter, pharmacologic cardioversion; Fetal tachycardia, sustained; Ventricular premature beats

Antiarrhythmic Drugs

Absorption: Oral: Nearly complete; may be decreased when administered with milk in pediatric patients. Protein binding: ~40%. Half-life elimination:(1)Newborns: Up to ?29 hours; 3 months: 11 to 12 hours; 12 months: 6 hours.(2)Children: ~8 hours.(3)Adolescents 12 to 15 years: ~11 to 12 hours.(4)Adults: ~20 hours (range: 12 to 27 hours); increased in patients with heart failure (NYHA Class III) or renal dysfunction. Time to peak, serum: ~3 hours (range: 1 to 6 hours). Excretion: Urine (30% [range: 10% to 50%] as unchanged drug); feces (5%).

Hypersensitivity to flecainide or any component of the formulation;pre-existing second- or third-degree AV block or with right bundle branch block when associated with a left hemiblock (bifascicular block) (except in patients with a functioning artificial pacemaker); cardiogenic shock; concurrent use of ritonavir.

C

present in breast milk

Ventricular arrhythmia, cardiac arrhythmia, cardiac failure, chest pain, dizziness, visual disturbances(accommodation disturbance, blurred vision, seeing spots), nausea, dyspnea

Atrial fibrillation/flutter or supraventricular tachycardia, maintenance of sinus rhythm: 50 mg Q12H; increase by 50 mg BID at 4-day intervals; maximum dose: 300 mg/day Ventricular arrhythmias (prevention)： 50-100 mg Q12H; increase by 50 mg BID at 4-day intervals; maximum: 400 mg/day. Some patients inadequately controlled with or intolerant to dosing every 12 hours may require dosing every 8 hours. Atrial fibrillation/flutter, pharmacologic cardioversion (off-label use): <70 kg: 200 mg; do not repeat dose within 24 hours ?70 kg: 300 mg; do not repeat dose within 24 hours Fetal tachycardia, sustained (off-label use): 100-300 mg/day in divided doses administered every 8 to 12 hours. Adjust dose to fetal response. Maximum dose: 450 mg/day.Targeted maternal blood levels between 0.2 and 1 mcg/mL. Ventricular premature beats (off-label use) : 50-200 mg Q12H. May increase by 50 mg BID at 4-day intervals; maximum: 400 mg/day.

Arrhythmias: BSA-directed dosing: Infants ?6 months: Initial: 50 mg/m2/day divided every 8 to 12 hours; may titrate dose at 4-day intervals; maximum daily dose: 200 mg/m2/day. Infants >6 months, Children, and Adolescents: Initial: 100 mg/m2/day divided every 8 to 12 hours; may titrate dose at 4-day intervals; maximum daily dose: 200 mg/m2/day. Weight-directed dosing: Infants, Children, and Adolescents: Oral: Initial: 1 to 3 mg/kg/day divided every 8 hours; may titrate dose at 4-day intervals; usual maintenance range: 3 to 6 mg/kg/day; maximum daily dose: 8 mg/kg/day. Higher doses have been associated with an increased risk of proarrhythmic effects

CrCl ?60 mL/minute/1.73 m2: No dosage adjustment necessary. CrCl >35 to <60 mL/minute/1.73 m2: Initial: No dosage adjustment necessary; consider obtaining serum trough concentrations to guide dosage adjustments; dose increases should be made cautiously and at intervals of ~7 days. CrCl ?35 mL/minute/1.73 m2: Initial: Administer 50% of the usual indication-specific initial dose in 1 to 2 divided doses; dose increases should be made no more frequently than every 7 days; the manufacturer's labeling recommends not to use flecainide if monitoring of trough concentrations is not available in patients with severe impairment Hemodialysis, intermittent (thrice weekly): Not dialyzable Initial: Administer 50% of the usual indication-specific initial dose in 1 to 2 divided doses; subsequent dose adjustments should preferentially be determined based on serum trough concentrations; dose increases should be made no more frequently than every 7 days Peritoneal dialysis: Not dialyzable Initial: Administer 50% of the usual indication-specific initial dose in 1 to 2 divided doses; subsequent dose adjustments should preferentially be determined based on serum trough concentrations; dose increases should be made no more frequently than every 7 days. CRRT: Not significantly removed Initial: Administer 50% of the usual indication-specific initial dose in 1 to 2 divided doses; subsequent dose adjustments should preferentially be determined based on serum trough concentrations; dose increases should be made no more frequently than every 7 days. PIRRT (eg, sustained, low-efficiency diafiltration): Not likely to be significantly removed: Initial: Administer 50% of the usual indication-specific initial dose in 1 to 2 divided doses; subsequent dose adjustments should preferentially be determined based on serum trough concentrations; dose increases should be made no more frequently than every 7 days

Unknown

Store in a cool, dry place below 30°C.